Highest-materiality recent filing
Sigyn Therapeutics raises ~$61.5k via three convertible notes at 35% discount
Entered three convertible note purchase agreements with Brio Capital, Osher Capital, and Lambda Venture Partners.
Three directors resign after D&O insurance lapse; $550K convertible note issued
Directors Richa Nand, Michael Ryan, and Christopher Wetzel resigned on Aug 7-8, 2025 due to lapse of D&O coverage.
Sigyn Therapeutics CFO Gerald DeCiccio Retires; CEO James Joyce Appointed Interim CFO
CFO Gerald DeCiccio retired effective February 26, 2025, with no disagreement with the company.
Sigyn Therapeutics appoints Michael Ryan to board effective Jan 11, 2025
Michael Ryan appointed to board; will serve until next stockholder meeting or successor elected.
Sigyn Therapeutics reduces authorized common shares to 100M via charter amendment
Filed Certificate of Amendment decreasing authorized common stock to 100 million shares (par value $0.0001).
Sigyn corrects prior error; debenture conversion adds 118,700 shares, 9.1% share increase
Corrected prior error: sellers were not controlled by an executive officer.
Sigyn Therapeutics exchanges 246,259 warrants for 184,699 restricted shares; no warrants outstanding
Exchanged 246,259 stock purchase warrants from 15 holders for 184,699 restricted common shares.
Sigyn Therapeutics issues 118,700 shares on conversion of $474,793 in debentures at $4.00/share
Holders of $474,793 in convertible debentures converted at $4.00/share; 118,700 restricted shares issued.
Holders converted $226,903 of Original Issue Discount Senior Convertible Debentures at avg. exercise price of $6.00/share.
Filed PCT application US24/28579 on May 9, 2024 for 'DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES'.
Sigyn Therapeutics converts $841k debentures to Series B Preferred; extends other debt to 2025
Brio Capital converts $220,420 debentures into 292.4 shares of Series B Convertible Preferred Stock.
Sigyn Therapeutics effects 1-for-40 reverse stock split; symbol gets 'D' suffix for 20 days
Reverse stock split effective January 30, 2024 at a 1-for-40 ratio.
Sigyn Therapeutics effects 1-for-40 reverse stock split effective Jan 31, 2024
Reverse stock split ratio of 1-for-40 effective 12:01 a.m. ET on January 31, 2024.
Sigyn Therapeutics enters share surrender agreement with CTO to cancel 2.56M shares
Craig Roberts, CTO and board member, surrenders 2,564,000 shares of common stock for cancellation.
Company reveals four therapeutic platforms: Sigyn Therapy, ImmunePrep, ChemoPrep, and ChemoPure, with pending patent for chemotherapy delivery system.
Sigyn Therapeutics removes CFO Jeremy Ferrell, appoints Jerry DeCiccio as replacement
Jeremy Ferrell removed as CFO effective immediately; no disagreements cited.
Sigyn Therapeutics reports conversion of $1.32M debentures into 7.3M shares
Holders converted $1,322,200 of Original Issue Discount Senior Convertible Debentures at $0.18/share.
Sigyn Therapeutics discloses PCT patent filing for chemo delivery enhancement system
PCT application entitled 'SYSTEM AND METHODS TO ENHANCE CHEMOTHERAPY DELIVERY AND REDUCE TOXICITY' submitted.
Sigyn Therapeutics amends convertible notes: extends maturity to Aug 2024, increases principal
Entered amendment agreements for $2,161,316 of convertible notes, extending maturity to August 30, 2024.
Sigyn Therapeutics exchanges warrants for common stock and Series A Preferred at $0.199/share
Entered Warrant Exchange Agreements with holders of warrants issued Oct 2020–Feb 2023.
Sigyn Therapeutics reports conversion of convertible debentures into 1,243,000 common shares
On June 2, 2023, $16,500 debenture converted into 33,000 shares at $0.50 per share.
Sigyn Therapeutics appoints Annette Marleau, Ph.D. as Chief Scientific Officer
Appointed Annette Marleau, Ph.D. as Chief Scientific Officer, effective immediately.
Sigyn Therapeutics appoints Jim Dorst, Richa Nand, and Christopher Wetzel to Board
Appointments effective October 10, 2022; each director brings distinct expertise.
Sigyn Therapeutics appoints Jeremy Ferrell as CFO, effective March 9, 2022
Jeremy Ferrell (CPA, MBA) appointed CFO; base salary $250,000/year, annual bonus up to 40%.
Sigyn Therapeutics completes animal study for Sigyn Therapy; safe and well-tolerated in 8 subjects
Eight porcine subjects received up to six-hour treatments; no serious adverse events reported.
Sigyn Therapeutics corrects typo in prior 8-K; confirms 320K share and warrant sale for $400K
Amendment corrects share count to 320,000 shares of common stock and warrants for 320,000 shares.
Sold 320,000 shares and warrants to purchase 320,000 shares for $400,000 gross proceeds.
Mr. James Joyce, our Chief Executive Officer, will serve as our interim Chief Financial Officer.
On February 26, 2025, our Chief Financial Officer, Mr. Gerald DeCiccio provided us a notice of retirement, effective immediately.
On January 11, 2025, our Board of Directors appointed Michael Ryan to our Board of Directors.
the Company removed Jeremy Ferrell from his position as CFO of the Company, effective immediately.
The Company has appointed Jerry DeCiccio to serve as the Chief Financial Officer of the Company, effective immediately.
The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.
The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.
The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.
The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jeremy Ferrell, CPA, MBA as Chief Financial Officer (“CFO”), effective March 9, 2022.
Max materiality 0.80 · Median 0.50 · Most common event other_material